ReviewQuantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: A systematic review
Section snippets
Methods
To ensure high methodologic quality, our systematic review adhered to 10 validated criteria for methodological rigor,11, 12 and 5 additional criteria were used to evaluate the scientific basis of treatment recommendations.12 We also adhered to the QUOROM (Quality of Reporting of Meta-analyses) guidelines13 for the reporting of meta-analyses of randomized trials. Systematic methods were used to identify articles for inclusion in the analysis, describe variations in study design and execution,
Study identification and selection
Our research strategies identified 740 potentially relevant studies. We excluded 678 studies: 527 studies did not include patients receiving venous thromboembolism therapy, 96 were reviews, 28 were nonrandomized, 22 were previously reported, and 5 were meta-analyses, systematic reviews or surveys. Of the remaining 62 original articles, 21 studies assessed change in clot-burden in randomized trials evaluating innovative therapy (subcutaneous low-molecular-weight heparin, which is now widely
Discussion
Our findings show a striking predictive correlation between change in clot-burden using quantitative assessment and subsequent long-term clinical outcome. A predictive relationship is suggested by the individual study population findings (Figure 1A, B, and C), irrespective of whether the treatment regimen was that under evaluation or usual care. The aggregate data show a striking predictive correlation for clot-burden change and subsequent recurrent venous thromboembolism using meta-regression
Acknowledgment
The authors thank Avneet Brar, Jeanne Sheldon, BA, and Charlene Wrona for their assistance with the manuscript.
References (32)
- et al.
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis
Blood
(2002) - et al.
Antithrombotic therapy for venous thromboembolic disease. ACCP Consensus Report
Chest
(1998) - et al.
Validation of an index of the quality of review articles
J Clin Epidemiol
(1991) - et al.
Improving the quality of reports of meta-analyses of randomized controlled trialsthe QUOROM statement
Lancet
(1999) - et al.
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
Lancet
(1992) - et al.
Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis
J Vasc Surg
(1999) - et al.
Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: A meta-analysis
J Thromb Haemost
(2004) - et al.
The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapythe emerging theme of delayed recurrence
Arch Intern Med
(1997) - et al.
Catheter-directed thrombolysis for lower extremity deep venous thrombosisreport of a national multicenter registry
Radiology
(1999) - et al.
Effects of low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis
N Engl J Med
(2001)
Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy
J Lab Clin Med
A randomised trial of subcutaneous low-molecular-weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis
Thromb Haemost
Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosisa Polish multicenter trial
Thromb Haemost
A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism
Arch Intern Med
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis
Ann Intern Med
The medical review article revisitedhas the science improved?
Ann Intern Med
Cited by (96)
Outcomes after Rivaroxaban Treatment of Extensive Deep Vein Thrombosis
2022, Annals of Vascular SurgeryPediatric May-Thurner Syndrome—Systematic review and individual patient data meta-analysis
2021, Journal of Thrombosis and HaemostasisThe Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
2020, Research and Practice in Thrombosis and HaemostasisThe role of vacuum assisted thrombectomy (AngioVac) in treating chronic venous thromboembolic disease. Systematic review and a single center's experience
2018, Cardiovascular Revascularization MedicinePresence and degree of residual venous obstruction on serial duplex imaging is associated with increased risk of recurrence and progression of infrainguinal lower extremity deep venous thrombosis
2018, Journal of Vascular Surgery: Venous and Lymphatic DisordersCitation Excerpt :The study by Cosmi et al considered RVO present when the diameter of the compressed proximal venous system was ≥2 mm, as compared with the ≥40% luminal diameter criteria used in the DACUS and extended DACUS studies, which we also used for our study.3-6,11 Furthermore, the time point for surveillance differed between the studies, with follow-up DUS being performed at 6 months by Cosmi et al,5 compared with 3 months in the DACUS studies.3-7 The presence of RVO is not a stable event, encompassing a wide range of phenotypes including chronic post-thrombotic occlusive disease and venous scarring.
Catheter-directed thrombolysis to avoid late consequences of acute deep vein thrombosis
2018, Thrombosis Research